Entocort Ec

Proteinuria, Asthma, Itching + 16 more

Treatment

20 Active Studies for Entocort Ec

What is Entocort Ec

Budesonide

The Generic name of this drug

Treatment Summary

Budesonide is a steroid that is used to treat a variety of inflammatory conditions related to the lungs and intestines, such as asthma, COPD, Crohn's disease, and ulcerative colitis. It was approved by the FDA in 1994 and is available under the brand names Pulmicort and Entocort.

Rhinocort

is the brand name

image of different drug pills on a surface

Entocort Ec Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rhinocort

Budesonide

1994

134

Effectiveness

How Entocort Ec Affects Patients

Budesonide is a medicine used to treat breathing and digestive illnesses by reducing inflammation. It is generally considered to be a safe medicine, although the dose varies from person to person. Patients should be informed of the risk of increased cortisol levels and adrenal gland suppression when taking this medication.

How Entocort Ec works in the body

Corticosteroids reduce inflammation by preventing blood vessels from widening and restricting the movement of white blood cells. These drugs also affect gene expression, leading to anti-inflammatory proteins like interleukin-10. Low doses of corticosteroids work to reduce inflammation, while higher doses suppress the immune system. Long-term use of high doses of corticosteroids can raise sodium levels and decrease potassium levels in the body.

When to interrupt dosage

The recommended portion of Entocort Ec is ruled by the diagnosed condition, including Vasomotor Rhinitis, Crohn's Disease and Chronic Obstructive Pulmonary Disease (COPD). Dosage is contingent upon the mode of administration (e.g. Enema; Kit; Tablet - Rectal or Respiratory (inhalation)) featured in the below table.

Condition

Dosage

Administration

Crohn Disease

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Colitis, Collagenous

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Proteinuria

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Nasal Congestion

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Asthma

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Itching

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Skin Diseases

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Acute Coryza

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Ulcerative Colitis

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Rhinitis, Vasomotor

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Nasal Polyps

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Crohn's Disease

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Eosinophilic Esophagitis

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Hypersensitivity

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

IGA Glomerulonephritis

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Sinusitis

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Crohn Disease

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

maintenance therapy

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Chronic Obstructive Pulmonary Disease

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder, Aerosol, powder - Respiratory (inhalation), Spray, metered, Nasal, Spray, metered - Nasal, Powder - Respiratory (inhalation), Powder, Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets - Oral, Capsule, delayed release pellets, Tablet, extended release, Tablet, extended release - Oral, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Nasal; Respiratory (inhalation), Aerosol - Respiratory (inhalation), Aerosol, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Oral, Inhalant - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Capsule - Oral, Capsule, Cutaneous, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Kit, Powder, metered - Respiratory (inhalation), Powder - Nasal; Respiratory (inhalation), Aerosol, metered - Nasal, Capsule, coated pellets, Kit - Rectal, Capsule, delayed release - Oral, Capsule, delayed release, Patch - Cutaneous, Patch

Warnings

Entocort Ec Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Status Asthmaticus

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

There are 20 known major drug interactions with Entocort Ec.

Common Entocort Ec Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Budesonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.

Entocort Ec Toxicity & Overdose Risk

It is uncommon to overdose on corticosteroids, but taking too much for a long period of time can lead to high levels of the hormone in the body and a decrease in the body's ability to produce its own hormones. In case of an overdose, it is recommended to reduce the dosage of corticosteroids temporarily. A 200mg dose of corticosteroids is enough to be lethal for female mice, while 400mg is enough to be lethal for male mice.

image of a doctor in a lab doing drug, clinical research

Entocort Ec Novel Uses: Which Conditions Have a Clinical Trial Featuring Entocort Ec?

516 active clinical trials are currently in progress to determine the potential of Entocort EC in mitigating Chronic Obstructive Pulmonary Disease (COPD), Ulcerative Colitis and Allergic conditions.

Condition

Clinical Trials

Trial Phases

Asthma

87 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Chronic Obstructive Pulmonary Disease

72 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

IGA Glomerulonephritis

0 Actively Recruiting

Ulcerative Colitis

17 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Sinusitis

0 Actively Recruiting

Crohn's Disease

53 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Colitis, Collagenous

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

maintenance therapy

0 Actively Recruiting

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Eosinophilic Esophagitis

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Polyps

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Entocort Ec Reviews: What are patients saying about Entocort Ec?

5

Patient Review

1/17/2015

Entocort Ec for Crohn's Disease

I started taking this medication in July. Since then, I've noticed a significant amount of hair loss; even the minoxidil treatment I was using previously has been ineffective.

4.3

Patient Review

12/5/2014

Entocort Ec for Crohn's Disease

I was dealing with some serious abdominal pain before trying this treatment. I'm glad to say that it was very effective in alleviating my discomfort.

3.3

Patient Review

9/9/2015

Entocort Ec for Crohn's Disease

After struggling with diarrhea for seven months and losing a lot of weight, these meds have been a godsend. However, I experience several side effects like hair loss, easy bruising, and oral thrush. It's something I'll have to discuss with my gastroenterologist to see if the benefits outweigh the cost.

2.7

Patient Review

12/23/2020

Entocort Ec for Crohn's Disease

I'm on my third week of Entocort, and while it has helped with some things (like diarrhea), I've found that it's giving me really bad gas and making me moody. Overall, it's not been a great experience.

2.7

Patient Review

9/26/2015

Entocort Ec for Crohn's Disease

I've found that this medication works better if taken in the morning, as it can cause insomnia when taken at night. I also experienced higher blood pressure and anxiety levels while taking this; however, it was effective in treating my Crohn's disease.

2.3

Patient Review

11/30/2014

Entocort Ec for Crohn's Disease

This medication has been effective in treating my lymphocytic colitis, but at a cost of severe headaches. I have reduced the dose to 6mg per day, which has helped manage my symptoms but is still quite expensive.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about entocort ec

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Entocort Ec

Image of McMaster Children's Hospital - Digestive Diseases Clinic in Hamilton, Canada.

Vancomycin for Ulcerative Colitis

18+
All Sexes
Hamilton, Canada

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Phase 2
Waitlist Available

McMaster Children's Hospital - Digestive Diseases Clinic

Neeraj Narula, MD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of The University of British Columbia in Vancouver, Canada.

Nutritional Therapy + Anti-TNFα for Crohn's Disease

9 - 17
All Sexes
Vancouver, Canada

Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.

Waitlist Available
Has No Placebo

The University of British Columbia

Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF

Have you considered Entocort Ec clinical trials?

We made a collection of clinical trials featuring Entocort Ec, we think they might fit your search criteria.
Go to Trials
Image of Cedars-Sinai Medical Center Otolaryngology Clinics in Los Angeles, United States.

Lavender Aromatherapy for Anxiety and Pain During Otolaryngologic Procedures

18+
All Sexes
Los Angeles, CA

The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The main questions it aims to answer are: * Does lavender aromatherapy help reduce anxiety and/or pain, and improve patient comfort during awake otolaryngologic procedures in the clinic? * Do patients subjectively find aromatherapy relaxing and/or beneficial during the procedure? Researchers will compare lavender aromatherapy to placebo (an odorless liquid) to see if lavender aromatherapy helps improve patient comfort during their awake procedure Participants will: * Have their scheduled procedure performed with lavender aromatherapy or placebo during the duration of the procedure * Take a short, less than 1 minute questionnaire both before and after the procedure, describing their levels of anxiety, pain and subjective impressions of the aromatherapy

Recruiting
Paid Trial

Cedars-Sinai Medical Center Otolaryngology Clinics

Ankona Ghosh, MD

Have you considered Entocort Ec clinical trials?

We made a collection of clinical trials featuring Entocort Ec, we think they might fit your search criteria.
Go to Trials
Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available
Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Entocort Ec clinical trials?

We made a collection of clinical trials featuring Entocort Ec, we think they might fit your search criteria.
Go to Trials